CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse aft...
Phase 1
Paris, France and 13 other locations
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 3
Paris, Île-de-France Region, France and 133 other locations
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia...
Phase 2, Phase 3
Paris, France and 37 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Paris, France and 27 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Paris, Île-de-France Region, France and 89 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Paris, France and 43 other locations
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain ...
Phase 3
Paris, France and 172 other locations
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...
Phase 3
Paris, France and 52 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Paris, Île-de-France, France and 34 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Paris, France and 48 other locations
Clinical trials
Research sites
Resources
Legal